Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
To obtain further information on the tolerability and efficacy of Atrovent® 500µg/2ml inhalation solution in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice
Interventions
DRUGAtrovent® Inhalation Solution
Sponsors
Boehringer Ingelheim
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
13 Years to 89 Years
Healthy volunteers
No
Inclusion criteria
* Patients of both genders, older than 40 years,who suffer from chronic obstructive Pulmonary disease * Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion
Exclusion criteria
* Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® 500µg/2ml Inhalation Solution * Patients who exhibited adverse drug reactions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Investigator assessment of improvement of the clinical picture of the course on a 6-point symptoms profile | up to 4 weeks after first study drug administration |
| Change in total severity of the clinical picture rated on a 4-point scale | Up to 4 weeks after first study drug administration |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of tolerability by investigator on a 4-point scale | Up to 4 weeks after first study drug administration |
| Assessment of efficacy by investigator on a 4-point scale | Up to 4 weeks after first study drug administration |
| Number of patients with adverse drug reactions | Up to 4 weeks after first study drug administration |
| Assessment of tolerability by patient on a 4-point scale | Up to 4 weeks after first study drug administration |
| Assessment of efficacy by patient on a 4-point scale | Up to 4 weeks after first study drug administration |
Outcome results
None listed